Microplastics (MPs) were characterized in surficial marine sediment (n = 36) and mussel (n = 29) samples collected along the British Columbia (BC) coast, Canada, using visual identification and Fourier Transform Infrared Spectrometry. MPs counts averaged 32.6 ± 5.3 particles per kg in sediment and 0.38 ± 0.04 particles per individual mussel (0.24 ± 0.04 /g of tissue). Victoria Harbour and the North Coast (Prince Rupert area) were MP hotspots, likely resulting from a combination of local sources and oceanographic conditions. Microfibers <1000 μm dominated the pattern in both matrices (61.1 % in sediment; 65.4 % mussels) highlighting the suspected role of textiles in the widespread distribution of MPs in the marine environment. Overall, polyester was dominant in sediment and mussels (54.1 % and 63.5 %, respectively), followed by polyethylene (16.2 % and 11.5 %, respectively). This is the first report of MPs in sediment and mussels along the coast of BC using standardized methods.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.marpolbul.2022.114273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The cold tolerance of the terrestrial slug, Ambigolimax valentianus.
J Comp Physiol A Neuroethol Sens Neural Behav Physiol
January 2025
Department of Zoology, University of British Columbia, Vancouver, BC, Canada.
Terrestrial molluscs living in temperate and polar environments must contend with cold winter temperatures. However, the physiological mechanisms underlying the survival of terrestrial molluscs in cold environments and the strategies employed by them are poorly understood. Here we investigated the cold tolerance of Ambigolimax valentianus, an invasive, terrestrial slug that has established populations in Japan, Canada, and Europe.
View Article and Find Full Text PDFState of the Art in Left Atrial Appendage Occlusion.
JACC Clin Electrophysiol
December 2024
Kansas City Heart Rhythm Institute and Research Foundation, Kansas City, Kansas, USA. Electronic address:
Left atrial appendage occlusion (LAAO) has become an important therapeutic target for stroke prevention in patients with nonvalvular atrial fibrillation. Over the past 2 decades, several advancements in LAAO devices (percutaneous and surgical) have been made for stroke prevention and arrhythmia therapy. However, there are several unanswered questions regarding optimal patient selection, the preferred LAAO approach and device, the management of periprocedural and postprocedural complications, including pericardial effusion, device-related thrombus, and device leaks.
View Article and Find Full Text PDFIncreasing Female Representation at Canadian Association of Radiologists Annual Scientific Meetings.
Can Assoc Radiol J
January 2025
Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Systematic review of outcome measures used in support programs designed to enhance the functioning for autistic children and adolescents and ICF content mapping.
Disabil Rehabil
January 2025
Postgraduate Program in Rehabilitation Sciences, Universidade Nove de Julho (UNINOVE), São Paulo, SP, Brazil.
Purpose: 1) To identify outcome measures used in support programs designed to enhance functioning in autistic children and adolescents, and 2) To map the content of these measures to the domains of the International Classification of Functioning, Disability and Health (ICF).
Methods: A systematic review was conducted. Searches were performed in Medline/PubMed, EMBASE and Virtual Health Library databases, with no restrictions imposed regarding language or year of publication.
Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot Study.
Cancers (Basel)
December 2024
BC Cancer, Vancouver Center, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.
Background/objectives: Pembrolizumab monotherapy is approved in Canada for first-line treatment of advanced NSCLC with PD-L1 ≥ 50% and no EGFR/ALK aberrations. However, approximately 55% of these patients do not respond to pembrolizumab, underscoring the need for the early intervention of non-responders to optimize treatment strategies. Distinguishing the 55% sub-cohort prior to treatment is a real-world dilemma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!